Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and other protein therapeutics to treat severe and life threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone626-305-5900
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$40.60 million
Profitability
Miscellaneous
Employees156
Next Earnings Date11/4/2019 (Estimated)
OptionableOptionable
Xencor (NASDAQ:XNCR) Frequently Asked Questions
What is Xencor's stock symbol?
Xencor trades on the NASDAQ under the ticker symbol "XNCR."
How were Xencor's earnings last quarter?
Xencor Inc (NASDAQ:XNCR) announced its quarterly earnings results on Tuesday, August, 6th. The biopharmaceutical company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.45) by $0.15. The biopharmaceutical company had revenue of $19.49 million for the quarter, compared to the consensus estimate of $7.58 million. Xencor had a return on equity of 8.40% and a net margin of 28.46%. View Xencor's Earnings History.
When is Xencor's next earnings date?
What price target have analysts set for XNCR?
10 brokerages have issued 1 year price targets for Xencor's stock. Their forecasts range from $21.00 to $67.00. On average, they anticipate Xencor's stock price to reach $45.2850 in the next year. This suggests a possible upside of 22.7% from the stock's current price. View Analyst Price Targets for Xencor.
What is the consensus analysts' recommendation for Xencor?
10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Xencor in the last year. There are currently 1 sell rating, 2 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Xencor.
What are Wall Street analysts saying about Xencor stock?
Here are some recent quotes from research analysts about Xencor stock:
- 1. Nomura analysts commented, "‘18087 (SSTR2xCD3) 2H19 to 1H20, 0 Est ASCO as Expected. SSTR2 is a validated target in NET and GIST, but these are solid tumors and suffer from tumor microenvironment effects and potential on-target toxicities. ‘18087 (SSTR2xCD3) is now the only bispecific in XNCR’s platform that we currently value. NVS to Our View. Recall, the clinical hold lifted in April; dosing to resume in coming weeks, but “tunable potency” still in question. Last update on clinicaltrials.gov was May 2 and included a Aug 2019 study completion date – we anticipate with appropriate study completion, NVS will return rights. More p 3. Checks – XNCRs’s Bispec C max -Dependent with Redesign." (8/8/2019)
- 2. According to Zacks Investment Research, "Xencor Inc. is a clinical-stage biopharmaceutical company. It develops antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer. Xencor Inc. is based in Monrovia, California. " (7/20/2019)
- 3. Cantor Fitzgerald analysts commented, ". We reiterate our Overweight rating and 12-month price target of $40. Xencor reported 1Q 2019 earnings and offered a Business Update. No Ultromaris royalties were booked because they are booked ~1-2 quarters in arrears vs. Alexion. The company did have $112M in revenue from February’s Genentech deal, resulting in positive EPS for the quarter. Ultromaris and MOR208 revenues remain fast-approaching, near-term revenue opportunities. Alexion (ALXN: NC) reported $25M in Ultromaris sales in 1Q 2019. Xencor receives a low-single-digit royalty on these revenues; we model a 2% royalty." (5/12/2019)
Has Xencor been receiving favorable news coverage?
Media headlines about XNCR stock have been trending somewhat negative on Sunday, InfoTrie Sentiment reports. The research group ranks the sentiment of news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Xencor earned a coverage optimism score of -1.3 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the next few days. View News Stories for Xencor.
Who are some of Xencor's key competitors?
Some companies that are related to Xencor include Catalent (CTLT), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Sarepta Therapeutics (SRPT), Beigene (BGNE), Dr.Reddy's Laboratories (RDY), Amarin (AMRN), ACADIA Pharmaceuticals (ACAD), Horizon Therapeutics (HZNP), Ascendis Pharma A/S (ASND), GW Pharmaceuticals PLC- (GWPH), Blueprint Medicines (BPMC), The Medicines (MDCO), United Therapeutics (UTHR) and Mirati Therapeutics (MRTX).
What other stocks do shareholders of Xencor own?
Who are Xencor's key executives?
Xencor's management team includes the folowing people:
- Dr. Bassil I. Dahiyat Ph.D., Co-Founder, CEO, Pres & Director (Age 49)
- Mr. John J. Kuch, Sr. VP of Fin., CFO & Sec. (Age 60)
- Dr. John R. Desjarlais, Sr. VP of Research & Chief Scientific Officer (Age 55)
- Dr. Paul A. Foster, Sr. VP & Chief Medical Officer (Age 65)
- Mr. Charles Liles, Associate Director and Head of Corp. Communications & Investor Relations
Who are Xencor's major shareholders?
Xencor's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Primecap Management Co. CA (13.16%), Price T Rowe Associates Inc. MD (10.60%), Vanguard Group Inc. (7.79%), BlackRock Inc. (7.64%), EcoR1 Capital LLC (4.13%) and Northern Trust Corp (1.08%). Company insiders that own Xencor stock include Bassil I Dahiyat, Edgardo Baracchini Jr, Edgardo Baracchini, Jr, John J Kuch, John R Desjarlais, John S Stafford III and Paul A Foster. View Institutional Ownership Trends for Xencor.
Which institutional investors are selling Xencor stock?
XNCR stock was sold by a variety of institutional investors in the last quarter, including Price T Rowe Associates Inc. MD, Artal Group S.A., Primecap Management Co. CA, Prudential Financial Inc., Victory Capital Management Inc., Cannell Peter B & Co. Inc., First Light Asset Management LLC and AQR Capital Management LLC. Company insiders that have sold Xencor company stock in the last year include John J Kuch and John R Desjarlais. View Insider Buying and Selling for Xencor.
Which institutional investors are buying Xencor stock?
XNCR stock was acquired by a variety of institutional investors in the last quarter, including Marshall Wace LLP, EcoR1 Capital LLC, Nuveen Asset Management LLC, BlackRock Inc., Marshall Wace North America L.P., Panagora Asset Management Inc., Louisiana State Employees Retirement System and Renaissance Technologies LLC. View Insider Buying and Selling for Xencor.
How do I buy shares of Xencor?
Shares of XNCR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Xencor's stock price today?
One share of XNCR stock can currently be purchased for approximately $36.91.
How big of a company is Xencor?
Xencor has a market capitalization of $2.09 billion and generates $40.60 million in revenue each year. The biopharmaceutical company earns $-70,410,000.00 in net income (profit) each year or ($1.31) on an earnings per share basis. Xencor employs 156 workers across the globe.View Additional Information About Xencor.
What is Xencor's official website?
How can I contact Xencor?
Xencor's mailing address is 111 WEST LEMON AVENUE, MONROVIA CA, 91016. The biopharmaceutical company can be reached via phone at 626-305-5900 or via email at [email protected]
MarketBeat Community Rating for Xencor (NASDAQ XNCR)
MarketBeat's community ratings are surveys of what our community members think about Xencor and other stocks. Vote "Outperform" if you believe XNCR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XNCR will underperform the S&P 500 over the long term. You may vote once every thirty days.
